Have a feature idea you'd love to see implemented?
Let us know!
EWTX Edgewise Therapeutics Inc
Price (delayed)
$34.62
Market cap
$3.25B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.55
Enterprise value
$3.21B
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need.
Highlights
Edgewise Therapeutics's debt has decreased by 12% YoY and by 5% from the previous quarter
Edgewise Therapeutics's equity has soared by 64% YoY but it has decreased by 4.6% from the previous quarter
The quick ratio has grown by 38% YoY but it has contracted by 18% from the previous quarter
The net income is down by 43% year-on-year and by 9% since the previous quarter
The EPS fell by 16% YoY
Key stats
What are the main financial stats of EWTX
Market
Valuations
Earnings
Shares outstanding
93.77M
Market cap
$3.25B
Enterprise value
$3.21B
Price to earnings (P/E)
N/A
Price to book (P/B)
6.33
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$115.88M
EBITDA
-$113.79M
Free cash flow
-$104.72M
Per share
Balance sheet
Liquidity
EPS
-$1.55
Free cash flow per share
-$1.12
Book value per share
$5.47
Revenue per share
$0
TBVPS
$5.69
Total assets
$531.65M
Total liabilities
$21.17M
Debt
$4.99M
Equity
$510.47M
Working capital
$502.27M
Debt to equity
0.01
Current ratio
30.24
Quick ratio
29.79
Net debt/EBITDA
0.34
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-26.7%
Return on equity
-28%
Return on invested capital
-30.9%
Return on capital employed
-22.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EWTX stock price
How has the Edgewise Therapeutics stock price performed over time
Intraday
-0.55%
1 week
-2.51%
1 month
33.56%
1 year
398.13%
YTD
216.45%
QTD
29.71%
Financial performance
How have Edgewise Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$136.17M
Net income
-$115.88M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 49% year-on-year and by 10% since the previous quarter
The net income is down by 43% year-on-year and by 9% since the previous quarter
Growth
What is Edgewise Therapeutics's growth rate over time
Valuation
What is Edgewise Therapeutics stock price valuation
P/E
N/A
P/B
6.33
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS fell by 16% YoY
The P/B is 153% more than the last 4 quarters average of 2.5
Edgewise Therapeutics's equity has soared by 64% YoY but it has decreased by 4.6% from the previous quarter
Efficiency
How efficient is Edgewise Therapeutics business performance
EWTX's ROA is down by 17% year-on-year but it is up by 3.3% since the previous quarter
Edgewise Therapeutics's ROE has decreased by 16% YoY but it has increased by 3.8% from the previous quarter
EWTX's ROIC is down by 12% YoY but it is up by 4% QoQ
Dividends
What is EWTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EWTX.
Financial health
How did Edgewise Therapeutics financials performed over time
The total assets has soared by 61% YoY but it has contracted by 4% from the previous quarter
The quick ratio has grown by 38% YoY but it has contracted by 18% from the previous quarter
Edgewise Therapeutics's debt is 99% less than its equity
Edgewise Therapeutics's equity has soared by 64% YoY but it has decreased by 4.6% from the previous quarter
Edgewise Therapeutics's debt to equity has shrunk by 50% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.